Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma

被引：1

作者：

Lipschitz, Noga ^{[1
]}

Earl, Brian R. ^{[1
,2
]}

Cripe, Timothy P. ^{[3
,4
]}

Samy, Ravi N. ^{[1
,5
,6
]}

机构：

[1] Univ Cincinnati, Coll Med, Dept Otolaryngol Head & Neck Surg, Cincinnati, OH USA

[2] Univ Cincinnati, Dept Commun Sci & Disorders, Coll Allied Hlth Sci, Cincinnati, OH USA

[3] Nationwide Childrens Hosp, Dept Pediat, Div Hematol Oncol Blood & Marrow Transplant, Columbus, OH USA

[4] Nationwide Childrens Hosp, Ctr Childhood Canc & Blood Dis, Res Inst, Columbus, OH USA

[5] Univ Cincinnati, Neurosensory Disorders Ctr, Gardner Neurosci Inst, 213 Albert Sabin Way,MSB 6407, Cincinnati, OH 45267 USA

[6] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA

来源：

CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY | 2020年 / 28卷 / 05期

关键词：

cholesteatoma; herpes simplex virus; oncolytic virotherapy; TALIMOGENE LAHERPAREPVEC; ACQUIRED CHOLESTEATOMA; VIRUS; SAFETY; ADENOVIRUS; MELANOMA; EFFICACY; PATHOGENESIS; COMBINATION; HSV-1;

D O I：

10.1097/MOO.0000000000000651

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Purpose of review To review the principles of oncolytic virotherapy and summarize the recent preliminary evidence on the efficacy of oncolytic virotherapy for cholesteatoma (CHST) treatmentin vitroin human CHST cells and in a gerbil CHST model. Recent findings The use of oncolytic virotherapy for nonmalignant lesions is innovative. In-vitro results showed that oncolytic herpes simplex virus 1 (oHSV) selectively targets and kills CHST cells. In a gerbil model of CHST, local oHSV injections were associated with a decrease in CHST volume and modulation of bony changes. Surgical treatment options for CHST are limited by high morbidity and recidivism, emphasizing the need for developing treatment alternatives. Preliminary results support the potential therapeutic effect of oncolytic virotherapy on CHST, yet further research is needed to evaluate this novel approach.

引用

页码：281 / 285

页数：5

共 50 条

[1] Immunotherapeutic potential of oncolytic virotherapy
Prestwich, Robin J.
Harrington, Kevin J.
Vile, Richard G.
Melcher, Alan A.
LANCET ONCOLOGY, 2008, 9 (07): : 610 - 612
[2] The Potential of Oncolytic Virotherapy in Synovial Sarcoma
Robinson, Steven I.
Clark, Susan M.
Iankov, Ianko D.
Viker, Kimberly B.
Concilio, Susanna C.
Galanis, Evanthia
MOLECULAR THERAPY, 2022, 30 (04) : 49 - 49
[3] Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy
Yun, Chae-Ok
CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2008, 10 (04) : 356 - 361
[4] The potential impact of hypoxia on the success of oncolytic virotherapy
Hay, JG
CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2005, 7 (04) : 353 - 358
[5] On the potential of oncolytic virotherapy for the treatment of canine cancers
MacNeill, Amy L.
ONCOLYTIC VIROTHERAPY, 2015, 4 : 95 - 107
[6] Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets
Hallden, Gunnel
Portella, Giuseppe
EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (10) : 945 - 958
[7] Oncolytic virotherapy - a promising approach in cancer treatment
Sharma, Rohit
Sil, Debayan
Kumar, Dinesh
Komal, Kumari
Kumar, Sourabh
Ghosh, Rashmi
Saini, Vipin
Kumar, Manish
EXPERT REVIEW OF ANTICANCER THERAPY, 2025, 25 (04) : 315 - 318
[8] Oncolytic virotherapy
Russell, Stephen J.
Peng, Kah-Whye
Bell, John C.
NATURE BIOTECHNOLOGY, 2012, 30 (07) : 658 - 670
[9] Oncolytic virotherapy
Cervantes-Garcia, Daniel
Ortiz-Lopez, Rocio
Mayek-Prez, Netzahualcoyotl
Rojas-Martinez, Augusto
ANNALS OF HEPATOLOGY, 2008, 7 (01) : 34 - 45
[10] Oncolytic Virotherapy
Sze, Daniel Y.
Reid, Tony R.
Rose, Steven C.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2013, 24 (08) : 1115 - 1122

← 1 2 3 4 5 →